ILMN - Illumina, Inc.
| Previous Close | 319.51 |
| Open | 317.96 |
| Bid | 303.00 x 1300 |
| Ask | 321.00 x 800 |
| Day's Range | 315.50 - 327.09 |
| 52 Week Range | 207.51 - 372.61 |
| Volume | 790,210 |
| Avg. Volume | 1,032,103 |
| Market Cap | 47.03B |
| Beta (3Y Monthly) | 2.04 |
| PE Ratio (TTM) | 69.25 |
| EPS (TTM) | 4.62 |
| Earnings Date | Jan 28, 2019 - Feb 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 359.75 |
- Motley Fool•17 hours ago
3 Healthcare Stocks That Have a Killer Advantage
They dominate their respective niche markets. And all three markets are growing rapidly.
- Motley Fool•2 days ago
Better Buy: EXACT Sciences Corporation vs. Illumina
Which of these two fast growers in the smarter choice for new money today?
- Zacks•3 days ago
Here's Why You Should Invest in Illumina (ILMN) Stock Now
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
- Zacks•4 days ago
Pacific Biosciences Offers Insights on Aedes aegypti Genome
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
- Zacks•4 days ago
Illumina (ILMN) Dips More Than Broader Markets: What You Should Know
Illumina (ILMN) closed the most recent trading day at $308.23, moving -0.95% from the previous trading session.
- Motley Fool•4 days ago
Is This the Real Reason Illumina Acquired Pacific Biosciences?
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
- Motley Fool•4 days ago
Here's Why Illumina's $1.2 Billion Acquisition Makes Sense
A 71% premium for a less-successful competitor may seem excessive, but timing is everything.
- Business Wire•5 days ago
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
- Investor's Business Daily•5 days ago
Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar
Medical technology stocks hit record highs in 2018 and three of the fastest-growing stocks among them have tacked on double-digit earnings growth for the past five years.
- GuruFocus.com•5 days ago
Despite Lofty Price, Illumina May Still Be a Buy
The company already had a dominant position in the fast-growing gene sequencing market before strengthening its position with the acquisition of Pacific Biosciences
InvestorPlace•6 days ago3 DNA Stocks That Are on the Uptrend
The future of genetic medicine — and DNA stocks — is extremely bullish over the long term. But as is normal of any emerging technology, there will be plenty of bumps along the road. The good news is that those bumps will provide many opportunities to buy DNA stocks along the way.
GuruFocus.com•7 days agoIllumina's Growth Shows No Signs of Slowing Down
Earlier in the month, Illumina (ILMN) made an aggressive and surprising move: acquiring Pacific Biosciences (PACB), one of its direct competitors, for $1.2 billion. To date, this is the largest acquisition that Illumina has ever made. Warning! GuruFocus has detected 1 Warning Sign with ILMN.
- Zacks•7 days ago
Is Illumina (ILMN) a Great Growth Stock?
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Illumina (ILMN).
- Motley Fool•8 days ago
Here's My Top Stock to Buy in November
It definitely has the DNA of a huge winner.
- MarketWatch•9 days ago
Biotech stocks have been hit hard — here are ones analysts like best for a rebound
Nine companies have majority ‘buy’ ratings, with upside potential of as much as 123%, according to analysts.
- Motley Fool•10 days ago
3 Growth Stocks Healthcare Investors Should Buy Now
Picking up shares in this research company, health insurer, and medical-device company could pay off for investors.
- Zacks•10 days ago
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
- Motley Fool•10 days ago
Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
- Zacks•11 days ago
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
Is (ILMN) Outperforming Other Medical Stocks This Year?
Markit•11 days agoSee what the IHS Markit Score report has to say about Illumina Inc.
Illumina Inc NASDAQ/NGS:ILMN
- Zacks•12 days ago
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
- Zacks•12 days ago
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
- Zacks•12 days ago
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
Illumina (ILMN) closed at $322.73 in the latest trading session, marking a -0.43% move from the prior day.
- Motley Fool•13 days ago
Twist Bioscience IPO: What Investors Need to Know
Investors can now buy shares in a leading synthetic biology company. But should they?
- Zacks•14 days ago
Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings
Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings
